Last updated: April 25, 2026
Who Supplies Fluticasone Propionate for Pharma Products?
Which companies supply fluticasone propionate API at industrial scale?
Fluticasone propionate is supplied globally through two main channels: (1) API and (2) finished-dose inhalation and nasal products. For R&D and commercialization planning, the most actionable supplier universe is the API market (not branded combination products).
The suppliers below are active in fluticasone propionate supply chains as manufacturers/distributors of the active ingredient and/or direct API sourcing networks used by pharma.
API manufacturers and API suppliers
| Supplier |
Supply role |
Typical product scope |
Notes for sourcing |
| Teva Active Pharmaceutical Ingredients |
API manufacturing / supply |
Steroids incl. inhaled/nasal corticosteroids |
Major upstream role in generic respiratory products |
| Aurobindo Pharma |
API manufacturing / supply |
Fluticasone propionate API and related respiratory intermediates |
Frequently supplies generic respiratory programs |
| Dr. Reddy’s Laboratories |
API manufacturing / supply |
Corticosteroid APIs |
Active in complex-API manufacturing |
| Torrent Pharmaceuticals / Torrent API networks |
API supply |
Respiratory APIs |
Used across generics procurement |
| Mylan / Viatris API supply chains |
Supplier via API contracts |
Corticosteroids |
Program-based procurement for inhaled/nasal products |
| Hetero Drugs / Hetero Labs |
API manufacturing / supply |
Respiratory and steroid APIs |
Common for generic inhalers and intranasals |
| Cipla API sourcing networks |
API procurement / supply |
Inhaled corticosteroids |
CMO-style supply for generics programs |
| Lupin |
API manufacturing / supply |
Respiratory APIs |
Upstream supply for generic portfolios |
Which suppliers provide fluticasone propionate excipient-formulation or “finished” dosing?
For commercialization work (clinical supply, commercial supply, line-fill, packaging, inhaler/nasal device compatibility), many firms procure via finished-dose manufacturers or their contracted filling and device partners.
| Supplier |
Supply role |
Delivery format |
Typical use case |
| Teva / Teva Pharmaceuticals |
Finished-dose manufacturer |
Nasal sprays, inhalers (branded and generic) |
Commercial launch scale |
| GlaxoSmithKline (GSK) |
Finished-dose originator supply |
Inhaled/nasal corticosteroid products |
Market benchmark; often higher-cost supply |
| AstraZeneca |
Finished-dose manufacturing ecosystem |
Respiratory products |
Procurement for inhalation programs and devices |
| Novartis |
Finished-dose manufacturing ecosystem |
Respiratory products |
Procurement for inhaler ecosystem |
| Actavis / Watson / Lupin fill-finish networks |
Contract manufacturing |
Nasal and inhalation finished dosage forms |
Device + filling integration |
Procurement reality for fluticasone propionate
- API and finished-dose supply differ materially. Many brand and generic companies source finished doses from fill-finish/device contractors even when they buy API internally.
- Respiratory formats drive supplier selection. Metered-dose inhaler (MDI), dry powder inhaler (DPI), and nasal spray production require different manufacturing and quality controls, with different vendor constraints for extractables/leachables and particulates.
- Regulatory dossiers are often the gating item. Companies generally award supply based on dossier readiness (CoA, DMF/ASMF linking, stability packages, and specific impurity profiles).
How to map suppliers to actual qualification pathways
What qualification artifacts typically matter for fluticasone propionate?
- Certificate of Analysis (CoA): impurity profile, water content, particle metrics (if applicable), assay and potency specs.
- Regulatory linkage: Drug Master File (USDMF) or Active Substance Master File (ASMF) referencing.
- Stability data: long-term and accelerated stability for the specific supplier lot and storage conditions.
- Supply chain controls: change control history, batch traceability, and deviation reporting cadence.
- Analytical methods: validated identity/purity methods (HPLC method equivalency, impurity standards).
Which documents typically screen suppliers out?
- No established DMF/ASMF or inability to cross-reference for the planned NDA/ANDA or to support bridging studies.
- No validated impurity method and no control strategy for known degradation products.
- No demonstrated stability for the exact packaging (for finished dosage) or retest/expiration shelf-life for the API.
Where does supply concentrate geographically?
Which regions dominate fluticasone propionate API supply?
| Region |
Supplier characteristics |
Typical throughput style |
| India |
Large generic/API manufacturing base, strong contract manufacturing |
High-volume API batches and recurring supply contracts |
| China |
Strong intermediate capacity; API manufacturing at scale |
Cost-competitive supply; heavier emphasis on impurity controls |
| Europe |
Specialized pharma manufacturing and high compliance standards |
Smaller-scale but dossier-heavy |
| US |
Focus on regulatory-ready dossiers and finished dose supply |
Direct integration into generic/brand programs |
Key Takeaways
- Fluticasone propionate supply splits into API manufacturing and finished-dose / device ecosystems, and qualification usually depends on DMF/ASMF linkage, impurity control, and stability packages.
- The most actionable supplier targets for an upstream procurement plan are major generic/API manufacturers with respiratory portfolios and dossier-ready quality systems.
- Finished-dose supply and device compatibility often matter as much as API sourcing for commercialization timelines.
FAQs
1) Who are the most common fluticasone propionate API supplier types?
Major generic API manufacturers with established steroid and respiratory portfolios, plus contract API supply networks tied to DMF/ASMF readiness.
2) Can a company source fluticasone propionate through distributor channels instead of API manufacturers?
Yes, distributors consolidate inventory and documentation, but qualification still hinges on DMF/ASMF, CoA coverage, and impurity method validation.
3) Does fluticasone propionate supply differ for nasal spray versus inhaler?
Yes. The device and formulation route (MDI, DPI, nasal spray) drives different manufacturing requirements and often different upstream fill-finish partners.
4) What data is most likely required to qualify an API supplier?
CoA with the supplier’s impurity profile, DMF/ASMF cross-reference capability, validated analytical methods, and full stability packages.
5) Are originator finished-dose companies also meaningful API suppliers?
They can be meaningful for finished dose and strategic supply chains, but API qualification for generics and pipeline programs typically still follows DMF/ASMF and impurity-control readiness rather than brand affiliation.
References (APA)
[1] European Medicines Agency (EMA). (n.d.). European public assessment reports (EPAR) and product information. https://www.ema.europa.eu/en
[2] U.S. Food and Drug Administration (FDA). (n.d.). Drugs@FDA: Product and application information. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] U.S. FDA. (n.d.). Drug Master Files (DMFs) and active pharmaceutical ingredient registration guidance. https://www.fda.gov/industry/fda-basics/drug-master-files-dmfs
[4] World Health Organization (WHO). (n.d.). WHO prequalification and quality-related guidance for pharmaceutical products and APIs. https://extranet.who.int/prequal/
